Opinion Voices | Letters to the Editor: When a few buyers control most medications, all consumers suffer
AI generated summary, Read the full article for complete information.
Estradiol patches, a widely used hormone therapy for menopause and certain cancer patients, have become scarce because four large buyers now control about 85 % of the medication market, allowing pharmacy benefit managers and narrow pharmacy networks to manipulate prices, limit generic competition, and prioritize corporate profit over patient access; critics argue that eliminating kickback schemes, banning narrow networks, and forcing price transparency would restore competition and lower costs, while others contend that the real issue lies in drug manufacturers reducing generic production and using tactics that block competition, making the current supply‑chain and reimbursement system unable to provide affordable, reliable access to the patches for women and men who depend on them.
AI generated summary, Read the full article for complete information.

Letters to the Editor: When a few buyers control most medications, all consumers suffer
'The safe harbor allowing kickbacks and market manipulation for pharmacy benefit managers needs to be rescinded, narrow networks outlawed and hospital master charges available for every bill over $20,' writes an L.A. Times reader.


